Earlier start for generic and biosimilar manufacturing in EuropeThe manufacturing of generics and biosimilars in the EU may begin from mid-2022 before patent protection of originator drugs expires, according to the latest legislation passed in the European parliament, Handelsblatt (p25) and FAZ (p21) report on Thursday (APMHE 62716).
Merck KGaA expands its specialty chemicals businessMerck will expand its specialty chemicals business in its performance materials division thanks to the successful $6.5 billion takeover of U.S. company Versum Materials, wrote FAZ on Saturday (p20) and Handelsblatt on Monday (p19) (APMHE 62667).
German health state secretary Stroppe leavesGerman health minister Jens Spahn has terminated the service of health state secretary Lutz Stroppe, who was in place since 2014, FAZ reports on Thursday (p24).
Germany planning obligatory measles vaccinationThe two political parties from the German ruling coalition have backed the introduction of obligatory measles vaccination for children, paving the way for a draft law to be presented by health minister Jens Spahn in May, FAZ reported on Sunday (p1), FAZ on Saturday (p1) and SZ on Monday (p1 & 5).
Criticism on lack of action in valsartan caseGerman experts criticised the European testing authority EDQM and Gerlan authorities for failing to carry out duties on drug manufacturing in the valsartan case, reported FAZ on Wednesday (p34)
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.